GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Chembio Diagnostics Inc (NAS:CEMI) » Definitions » Operating Margin %

Chembio Diagnostics (Chembio Diagnostics) Operating Margin % : -35.97% (As of Dec. 2022)


View and export this data going back to 2004. Start your Free Trial

What is Chembio Diagnostics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Chembio Diagnostics's Operating Income for the three months ended in Dec. 2022 was $-3.30 Mil. Chembio Diagnostics's Revenue for the three months ended in Dec. 2022 was $9.16 Mil. Therefore, Chembio Diagnostics's Operating Margin % for the quarter that ended in Dec. 2022 was -35.97%.

Warning Sign:

Chembio Diagnostics Inc operating margin has been in a 5-year decline. The average rate of decline per year is -19.3%.

The historical rank and industry rank for Chembio Diagnostics's Operating Margin % or its related term are showing as below:

CEMI' s Operating Margin % Range Over the Past 10 Years
Min: -72.08   Med: -32.02   Max: 3.4
Current: -42.21


CEMI's Operating Margin % is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: -5.15 vs CEMI: -42.21

Chembio Diagnostics's 5-Year Average Operating Margin % Growth Rate was -19.30% per year.

Chembio Diagnostics's Operating Income for the three months ended in Dec. 2022 was $-3.30 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2022 was $-20.40 Mil.


Chembio Diagnostics Operating Margin % Historical Data

The historical data trend for Chembio Diagnostics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chembio Diagnostics Operating Margin % Chart

Chembio Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.11 -37.29 -72.08 -65.01 -42.21

Chembio Diagnostics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -48.68 -26.61 -67.87 -52.51 -35.97

Competitive Comparison of Chembio Diagnostics's Operating Margin %

For the Diagnostics & Research subindustry, Chembio Diagnostics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chembio Diagnostics's Operating Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Chembio Diagnostics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Chembio Diagnostics's Operating Margin % falls into.



Chembio Diagnostics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Chembio Diagnostics's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-20.402 / 48.34
=-42.21 %

Chembio Diagnostics's Operating Margin % for the quarter that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2022 ) / Revenue (Q: Dec. 2022 )
=-3.296 / 9.162
=-35.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chembio Diagnostics  (NAS:CEMI) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Chembio Diagnostics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Chembio Diagnostics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chembio Diagnostics (Chembio Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
3661 Horseblock Road, Medford, NY, USA, 11763
Chembio Diagnostics Inc is a company that develops, manufactures, and commercializes point-of-care diagnostic tests that detect infectious diseases. The products of the company include rapid tests for the detection of HIV 1/2 antibodies and a multiplex rapid test for the detection of HIV and syphilis antibodies. The company offered rapid medical tests that are offered in Africa, Asia, Europe, and the Middle East, Latin America and the United States, of which key revenue is derived from Latin America.
Executives
Perceptive Credit Advisors, Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Leslie Teso-lichtman director C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Charles Caso officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Paul Angelico officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Lawrence J. Steenvoorden officer: See remarks C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
David William Bespalko director 29 CEDAR DRIVE, ALLENDALE NJ 07401
David Acheson director C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Richard Eberly officer: See Remarks 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John Gary Potthoff director 6140 SPANISH OAKS CLUB BLVD., AUSTIN TX 78738
Javan Esfandiari officer: Senior Vice President 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Robert Passas officer: See Remarks 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Polan Mary Lake Ph D director STANFORD UNIVERSITY SCHOOL OF MEDICINE, 300 PASTAUR DR ROOM HH333, STANFORD CA 94305-5317
Neil A Goldman officer: Executive VP and CFO 3661 HORSEBLOCK RD, MEDFORD NY 11763

Chembio Diagnostics (Chembio Diagnostics) Headlines